Log in with your email address username.

×

Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Correspondence] Concerns about cardiotoxicity in the HERA trial

In the HERceptin Adjuvant (HERA) trial (Feb 16, p 1195),1 the investigators reported that cardiac toxicity remained low in all groups and occurred mostly during the treatment phase. Cardiac assessments included repeated use of the New York Heart Association classification and left ventricular ejection fraction assessed by a cardiologist. However, the absence of information regarding radiation-related cardiac hazard might have caused misinterpretation of the data.

email